David S. Barlow has served as the Chairman of our Board of Directors since early 2000 and as our Chief Executive Officer since January 2003. He has more than 25 years of experience in the global biopharmaceutical industry. Prior to Molecular Insight, Mr. Barlow was President, Pharmaceuticals at Sepracor Inc. During his tenure at Sepracor from 1993 to 1999, Pharmaceuticals was built into a fully integrated pharmaceutical company with a strong product pipeline, a complete research and development and United States sales and marketing capability, and several significant corporate partnerships. Before Sepracor, Mr. Barlow worked for Rhone-Poulenc Rorer, where he led the turnaround of the Armour Pharmaceutical Division. He had previously worked for Pfizer Inc and ARES-Serono in a variety of business development and marketing positions. Mr. Barlow is a Trustee of McLean Hospital, Bates College, and Newton Country Day School and on the Board of Directors of New River Pharmaceuticals. He is also a member of the President’s Council at Massachusetts General Hospital. Mr. Barlow received a B.A. from Bates College and an M.B.A. from Stanford University.

John W. Babich, Ph.D., a founder of the company in 1997, serves as our President and Chief Scientific Officer, and is a member of our Board of Directors. He has been an active researcher in the field of molecular imaging and targeted radionuclide therapy for the past 25 years. Prior to joining the company, he was Assistant Professor of Radiology at Harvard Medical School and Staff Radiopharmaceutical Chemist at Massachusetts General Hospital (MGH), Boston, Massachusetts. Prior to joining MGH, Dr. Babich was Principal Scientist and Head of the Radiopharmaceutical Section at the Institute of Cancer Research in England. Dr. Babich’s current research efforts focus on molecular imaging in cardiovascular disease, oncology and neurology. His previous research experience includes detection of breast and colorectal cancer using monoclonal antibodies, pharmacological and in vivo biological studies of novel small molecules for targeted therapy of neuroblastoma, the use of peptide-based molecular imaging agents for the detection of infection and cancer, and the use of positron emission tomography for the study of drug behavior in humans. He has published more than 100 research articles in a variety of peer-reviewed journals as well as several book chapters and invited reviews. He is inventor or co-inventor of seven issued and pending patents licensed to or property of the company. He is also co-inventor of a cardiac imaging product currently marketed by Mallinckrodt-TycoHealthcare, Inc. as Ultra-Tag. Dr. Babich recently served as President of the Society of Nuclear Medicine’s Radiopharmaceutical Science Council. Dr. Babich received a B.S. in Pharmacy from St. John’s University, an M.S. from University of Southern California, and a Ph.D. from the University of London.

Daniel Frank has served as a member of our Board of Directors since 2004. Since 2001, he has worked at Cerberus Capital Management, L.P., a private investment firm. From 1999 to 2001, Mr. Frank served as a Managing Director and Portfolio Manager of ACI Capital Strategic Fund, a New York-based hedge fund, and prior to that he served as a portfolio manager for Chatterjee/ Soros Fund Management. From 1979 to 1996, Mr. Frank was employed by Fidelity Management and Research (Fidelity Investments). While at Fidelity, Mr. Frank served as Assistant Portfolio Manager to Peter Lynch on the Magellan Fund and as Vice President and sole Portfolio Manager, for over a decade, of the Fidelity Strategic Opportunities/ Special Situations Fund. In 1996, Mr. Frank was ranked by Barron’s magazine as one of the Top 100 U.S. Mutual Fund Managers. Mr. Frank served on the Board of Directors of i-STAT Corporation from 2001 until its sale to Abbott Laboratories in 2003. From 1986 until its sale in 1996, Mr. Frank was board member and largest stockholder of Corsearch, a New York-based trademark research firm that is now part of CCH-Wolters Klower Inc. Mr. Frank received a B.S. in Business Administration from Boston University School of Management.

Scott Gottlieb, MD, has served as a member of our Board of Directors since 2007. Dr. Gottlieb, a practicing physician, joined the American Enterprise Institute earlier this year after several years at the U.S. Food and Drug Administration (FDA). Dr. Gottlieb was the Deputy Commissioner for Medical and Scientific Affairs at the FDA from 2005 to 2007.  Prior to his appointment as Deputy Commissioner, he served at the FDA in a number of senior capacities, including Senior Advisor for Medical Technology for the FDA Commissioner and Director of Medical Policy Development. During his time in government, he also served as Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS), and is a frequent contributor to leading journals and publications.  Dr. Gottlieb received his M.D. degree from the Mount Sinai School of Medicine in New York and his B.A. degree in economics from Wesleyan University in Middletown, Connecticut.

David M. Stack has served as a member of our Board of Directors since 2006 and has more than 25 years of experience in the pharmaceutical and biotechnology industries. Mr. Stack has been Executive Partner of MPM Capital since 2005 and a Managing Partner of Stack Pharmaceutical, Inc. since 2004. From 2001 until 2004 he was President, Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President, General Manager at Innovex, Inc., where he held positions of increasing responsibility from 1995. He was Vice-President, Business Development/Marketing at Immunomedics from 1993 until 1995 and prior to that he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, most recently as Director, Business Development and Planning, Infectious Disease, Oncology, and Virology. He currently serves as a Director of Bio-Imaging Technologies, Inc., Medsite, Inc., PepTx, Inc. and ORx Pharma, Pty. Ltd. Mr. Stack holds a B.S. degree in Biology from Siena College and a B.S. degree in Pharmacy from the Albany College of Pharmacy.

Harry Stylli, Ph.D. has served as a member of our Board of Directors since 2004. Dr. Stylli has been Chief Executive Officer of Sequenom since 2005. From 2004 until 2005 he was President and Chief Executive Officer of Xenecor. Dr. Stylli co-founded Aurora Biosciences in 1995, where he served as Senior Vice President of Screening Technology and New Ventures from 2001 to 2002 and as Senior Vice President of Commercial Development from 1999 to 2001. In 2001, following the merger between Aurora and Vertex Pharmaceuticals, Dr. Stylli served as President of Aurora Biosciences and Panvera. From 2002 to 2003, he served as President and Chief Executive Officer of CovX Pharmaceuticals. From 1987 to 1995, Dr. Stylli held varying positions of increasing responsibility in the global discovery organization of GlaxoSmithKline. He currently serves as a Director of Scitegic, a privately-held bioinformatics company. Dr. Stylli received a B.S. from the University of East London, an M.B.A from Open University in the United Kingdom and his Ph.D. from London University.

Lionel Sterling has agreed to join our Board of Directors as of the listing of our common stock on the Nasdaq National Market. In 1987, Mr. Sterling founded Equity Resources Inc., a private investment firm, where he has served as President since 1987. He is currently a member of the Board of Directors of Third Wave Technologies. From 1988 to 1993, Mr. Sterling served as co-Founder and Managing Partner of Whitehead/Sterling, a private investment firm, and from 1981 to 1985, he served as Chairman of the Board of Rayovac Corporation. In addition, from 1981 to 1982, Mr. Sterling served as Executive Vice President and member of the Board of Directors of United Brands Company, and from 1974 to 1981, he was with American Can Company, where he served as a Chief Financial Officer and Sector Executive. He has also served as Vice President and a Managing Director of Donaldson, Lufkin & Jenrette, Inc.’s venture capital and private investment activities, as well as having held various operating and financial responsibilities at ITT Corporation within its technology and services divisions. Mr. Sterling has held a number of public and private Board positions and has served as an advisor to a number of venture capital and buyout firms, as well as being an investor in a number of privately-held companies. Mr. Sterling has been on the Board of Overseers of New York University Schools of Business and on the Board of Overseers of the Dartmouth Institute, and serves with a number of non-profit organizations. Mr. Sterling received a B.A. from Brooklyn College in New York and an M.B.A. in Finance from New York University.